TABLE 1

Patients and Treatment Characteristics

Patient	Diagnosis	Age (y)	Sex	BSA (m²)	Injected activities									Follow-up (mo)
Patient	Diagnosis	Age (y)	Sex	BSA (m²)						Cycle 1 (GBq)	Cycle 2 (GBq)	Cycle 3 (GBq)	Cycle 4 (GBq)	Follow-up (mo)	Cycle 5 (GBq)
1	Carcinoid	64	F	1.58	2.9	2.9	2.9	2.9		64.1
2	Islet cell F	75	F	1.73	2.9	2.9	2.9	2.9		64.8
3	Islet cell NF	63	F	1.50	4.0	3.9	3.9	3.7		62.2
4	Carcinoid	47	F	1.50	3.3	3.3	3.3	3.3		18.0*
5	Carcinoid	64	M	1.94	9.0	2.5				38.2
6	Carcinoid	57	F	1.95	10.5	5.3				19.6
7	Carcinoid	42	M	1.55	10.0	10.0				34.1
8	Islet cell NF	63	M	1.68	11.6	3.0				26.8
9	Carcinoid	60	M	1.82	13.7	4.7	4.5			28.0
10	Carcinoid	62	M	1.74	11.0					18.7
11	Islet cell NF	63	M	1.88	3.4	3.4	3.4	3.4	3.3	61.4
12	Islet cell F	43	F	1.51	3.8	3.8	3.8	3.8		51.3
13	Unclassified	55	M	2.06	9.3	5.9				45.3
14	Islet cell NF	63	M	1.78	14.4	4.6				23.0
15	Islet cell F	44	F	1.75	2.6	2.5	2.5	2.5		18.0
16	Carcinoid	58	M	1.81	1.7	1.5	1.7	1.7	1.7	24.1*
17	Islet cell F	55	F	1.75	2.1	2.1	2.1	2.1		65.4
18	Carcinoid	52	F	1.64	7.5	3.7				36.0

↵* Patient died from tumor progression during follow-up.
BSA = body surface area; carcinoid = carcinoid tumor; islet cell F = functioning islet cell carcinoma; islet cell NF = nonfunctioning islet cell carcinoma.